Hypoglycemia: A closer look at a community pharmacist's impact in optimizing diabetes care.
Urvinder Kaur, Matthew Machado, Amee Mistry
https://pubmed.ncbi.nlm.nih.gov/35550730/Actively Recruiting
Led by Kaiser Permanente · Updated on 2026-10-14
250
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are evaluating a new approach to prevent severe low blood sugar hypoglycemia in adults with type 2 diabetes who are at high risk for this condition. Hypoglycemia can cause serious health problems including falls, heart issues, and memory loss, yet it is often not well managed. The study aims to test whether a clinical pharmacist, called a Hypoglycemia Champion, using a clear guideline named Hypoglycemia on a Page HOAP can improve the safety of diabetes treatment compared to usual care. Participants are divided into two groups. One group receives proactive outreach and support from the clinical pharmacist applying the HOAP guidelines to manage and reduce hypoglycemia risk. The other group receives standard diabetes care after the HOAP guideline is shared system-wide. The pharmacist contacts patients mainly by phone and electronic messaging to provide personalized care and adjust treatments. All medical decisions remain with each patients regular healthcare team. During the study, participants will have their diabetes medication use, particularly the discontinuation of certain drugs that increase hypoglycemia risk, monitored over six months. Researchers will also track the use of continuous glucose monitors CGM, prescriptions for glucagon, blood sugar control, and hospital visits due to hypoglycemia. The study includes assessments at multiple time points up to one year to evaluate safety, treatment changes, and health outcomes, aiming to improve patient safety and reduce healthcare costs.
CONDITIONS
Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
L
Lisa K Gilliam, MD, PhD
A
Andrew J Karter, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kaiser Permanente
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Pharmacist outreach (HOAP) | Usual care | Standard diabetes care (ADA) |
|---|---|---|---|
| what it is | Structured outreach by a clinical pharmacist using the HOAP (Hypoglycemia on a Page) algorithm to identify and engage high‑risk patients for hypoglycemia prevention | Standard diabetes care provided by the usual care team after system‑wide dissemination of HOAP principles | Guideline‑recommended diabetes management emphasizing risk mitigation for hypoglycemia, including use of CGM and individualizing glucose‑lowering therapies |
| role in trial | Investigational behavioral intervention used for proactive outreach to high‑risk patients | Control condition representing usual care after HOAP dissemination | Represents current recommended care under ADA guidelines, not a trial arm |
| primary use | To reduce hypoglycemia risk by prompting safer diabetes medication regimens through pharmacist‑led deprescribing and outreach | Usual management without proactive pharmacist outreach, relying on existing care team practices | General strategies for hypoglycemia prevention such as CGM use, cautious prescribing of high‑risk medications, and individualized glycemic targets |
| how it is given or performed | Pharmacist reviews charts, contacts patients via phone and secure messaging or letter, with follow‑up calls for non‑responders | Routine care provided by primary care and diabetes teams without structured pharmacist outreach | Care provided through usual clinical visits using guideline tools like CGM and medication review |
| evidence status | Led to safer prescribing (28.1% vs 15.8%) and eliminated hypoglycemia‑related acute care events at 6 months | Lower rate of safer prescribing (15.8%) and 5.3% experienced hypoglycemia‑related ED or hospital visit | Guidelines advise CGM and medication adjustments to reduce hypoglycemia risk, but evidence varies by implementation |
| important risks | No adverse events reported; intervention is behavioral rather than pharmacologic | Standard care risks include ongoing hypoglycemia risk from high‑risk medications | Guidelines caution against use of insulin and sulfonylureas due to hypoglycemia risk |
| important limitations | Requires pharmacist resources and may not be generalizable outside integrated health systems | May under-recognize hypoglycemia risk due to lack of structured pharmacist outreach | Guidelines may not ensure implementation; real‑world uptake of CGM and deprescribing varies |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Participants are randomly assigned to receive proactive support from a clinical pharmacist using HOAP guidelines or to continue usual diabetes care after HOAP is shared system-wide.
Initial phone call and up to two follow-up calls for outreach; ongoing monitoring through healthcare providers
Duration - Up to 12 months
Participants are monitored for diabetes medication changes, hypoglycemia events, and health outcomes at 3, 6, and 12 months after starting the study.
Regular data collection from medical records and healthcare visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Urvinder Kaur, Matthew Machado, Amee Mistry
https://pubmed.ncbi.nlm.nih.gov/35550730/Hae Mi Choe, Sonya Mitrovich, Daniel Dubay...
https://pubmed.ncbi.nlm.nih.gov/15839185/Andrew J Karter, Howard H Moffet, Jennifer Y Liu...
https://pubmed.ncbi.nlm.nih.gov/29710182/Kasia J Lipska, Joseph S Ross, Yun Wang...
https://pubmed.ncbi.nlm.nih.gov/24838229/Nakiya Whitfield, Patrick Gregory, Beiyu Liu...
https://pubmed.ncbi.nlm.nih.gov/35151583/Rita L Hui, Christopher C Chang, Fang Niu...
https://pubmed.ncbi.nlm.nih.gov/31347983/Andrew J Karter, Melissa M Parker, Howard H Moffet...
https://pubmed.ncbi.nlm.nih.gov/19500161/Lisa K Gilliam, Melissa M Parker, Minnie W Chen...
https://pubmed.ncbi.nlm.nih.gov/41706448/Melissa M Parker, Howard H Moffet, Alyce Adams...
https://pubmed.ncbi.nlm.nih.gov/26078413/Andrew J Karter, E Margaret Warton, Kasia J Lipska...
https://pubmed.ncbi.nlm.nih.gov/28828479/Kaiser Permanente
Lead Sponsor